Mitochondria: the gateway for tamoxifen-induced liver injury
Mariana P C Ribeiro1, Armanda E Santos1, José B A Custódio1
1Center for Neuroscience and Cell Biology, University of Coimbra, 3000-354 Coimbra, Portugal; Laboratory of Biochemistry, Faculty of Pharmacy, University of Coimbra, 3000-548 Coimbra, Portugal.
Abstract:
Tamoxifen (TAM) is routinely used in the treatment of breast carcinoma. TAM-induced liver injury remains a major concern, as TAM causes hepatic steatosis in a significant number of patients, which can progress toward steatohepatitis. Liver toxicity is generally believed to involve mitochondrial dysfunction and TAM exerts multiple deleterious effects on mitochondria, which may account for the hepatotoxicity observed in patients treated with TAM. Endoxifen (EDX), a key active metabolite of TAM that is being investigated as an alternative to TAM in breast cancer therapy, slightly affects mitochondria in comparison with TAM and this demonstration well correlates with the absence of alterations in the clinical parameters of individuals taking EDX. The steady-state plasma concentrations of TAM and its active metabolites EDX and 4-hydroxytamoxifen (OHTAM) in patients taking TAM are highly variable, reflecting genetic variants of CYP2D6 involved in TAM metabolism. Besides de genetic polymorphisms, the intake of drugs that influence the enzymatic activity of CYP2D6 compromises the therapeutic efficiency of TAM. The knowledge of the impact of the variability of TAM metabolism in the breast cancer treatment explains the discrepant outcomes observed in patients taking TAM, as well as the individual variability of idiosyncratic liver injury and other sides effects observed. Therefore, and contrarily to the clinical use of EDX, the need of therapeutic drug monitoring and a regular assessment of liver function biomarkers should be considered in patients under therapies with TAM. In this review we focus on the mitochondrial effects of TAM and its metabolites and on the role played by mitochondria in the initiating events leading to TAM-induced hepatotoxicity, as well as the clinical implications.
Insights
Tamoxifen (TAM) causes liver injury by damaging mitochondria, while its metabolite endoxifen (EDX) is safer. Monitoring TAM levels and liver function is crucial due to variable metabolism and toxicity risks.
Area of Science:
- Hepatology
- Mitochondrial Biology
- Pharmacology
Background:
- Tamoxifen (TAM) is a standard breast cancer treatment.
- TAM frequently causes liver injury, including hepatic steatosis and steatohepatitis.
- Mitochondrial dysfunction is a key mechanism in TAM-induced hepatotoxicity.
Purpose of the Study:
- To review the mitochondrial effects of TAM and its metabolites.
- To elucidate the role of mitochondria in TAM-induced liver injury.
- To discuss clinical implications for TAM therapy.
Main Methods:
- Review of existing literature on TAM, its metabolites, and mitochondrial function.
- Analysis of studies investigating TAM's impact on liver cells and mitochondria.
- Correlation of metabolic variability with clinical outcomes and liver toxicity.
Main Results:
- TAM significantly impacts mitochondrial function, contributing to liver damage.
- Endoxifen (EDX), a TAM metabolite, shows minimal mitochondrial effects and is better tolerated.
- CYP2D6 genetic polymorphisms and drug interactions cause variable TAM metabolism and unpredictable toxicity.
Conclusions:
- Mitochondrial dysfunction is central to TAM-induced hepatotoxicity.
- EDX presents a potentially safer alternative to TAM.
- Therapeutic drug monitoring and liver function assessment are vital for patients on TAM therapy.
More Related Videos
10:39Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module
Published on: June 18, 2015
09:32Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity
Published on: October 17, 2025
Related Concept Videos
Electron Transport Chain: Complex I and II
ROS generation is regulated and maintained at moderate levels necessary...
Bioactivation and Tissue Toxicity
Drug Toxicity: Risk factors
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Drug Toxicity: Overview
